Company intelligence / Profile preview

Ashbury Biologicals

North York (Toronto area), Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Ashbury Biologicals is a Canadian biotech company focused on the development of herbal drug products and nutritional supplements. Its lead program, parthenolide, targets NF-kappaB for potential use in lymphoma. The company has formed strategic partnerships to advance its pipeline but does not have any approved drugs as of June 2025.

Therapeutic areas: Oncology
Modalities: Small molecule (herbal-derived compounds)Plant-based healthcare products
Industry: Biotech

Drug pipeline

1 asset

parthenolide

Unknown

Partnerships

SSP Co. Ltd. (Japan) – strategic partnership for herbal/nutritional product development and commercialization

Beyond the preview

Go deeper on Ashbury Biologicals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ashbury Biologicals.